Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Game-Changing ‘Bio-Glue’ Could End Use of Surgical Sutures and Staple

By HospiMedica International staff writers
Posted on 24 May 2022

Tissue adhesive washout and detachment are major issues for medical practitioners and may prove fatal for patients, especially when the separation happens in vital organs like the lungs, liver and the heart. More...

These organs – even when healthy – undergo frequent movement (contractions and relaxations) due to physiological needs, which cause additional strain on tissue adhesives. Now, a new ‘bio-glue’ has the capability to replace and revolutionize tissue adhesives (like fibrin glue) currently utilized in clinical settings, triage situations and mass casualty incidents. The discovery of the new bio-glue designed using materials already approved by the U.S. Food and Drug Administration (FDA) for other applications may mean an end to surgical sutures and staples made of plastic or stainless steel.

A team of researchers at Western University (Ontario, Canada) and University of Manitoba (Winnipeg, Canada) has developed the first-ever hydrophobic (water-hating) fluid, which displaces body fluids surrounding an injury allowing for near-instantaneous gelling, sealing and healing of injured tissue. Since the new bio-glue forms a strong bond with the adjacent tissue, it virtually eliminates detachment. In extensive preclinical studies, it was able to seal a punctured lung, heart, artery and even a fractured skull. For the new bio-glue, the primary material is silicone, which does not absorb the water from the tissue, so it sticks.

“Tissue adhesives that can perform in the presence of blood, water and other proteins in the body are the holy grail for instant wound closure and hemostasis, especially when time is critical in rescue operations and emergency responses,” said Kibret Mequanint, a Western chemical and biochemical engineering professor. “Fibrin glue, and the like, often fail to displace fluids around an injury. This failure means (current tissue adhesives) never strongly adhere to the wound and often detach within the first hour or two.”

“This new bio-glue is transformative in its deceptive simplicity,” added Mequanint. “There was no tissue reaction to it and the healing was fast. Silicone forms a strong adhesion, so you don’t have to worry after the repair that it’s going to reopen and cause more problems beyond the initial injury.”

Related Links:
Western University 
University of Manitoba 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.